The Cancer Epigenetics Society is very excited to announce the appointment of Dr. Peter Jones, Chief Scientific Officer of Van Andel Research Institute (VARI, Grand Rapids, MI, USA), as co-Editor-in-Chief of the Cancer Epigenetics journal series.
Dr. Jones is a world renown DNA methylation expert who was first to show that 5-azacytidine is a demethylating agent, the first epigenetic drug to be approved for cancer therapy. Prior to his current position as Van Andel Research Institute CSO, Dr. Jones served as Director of the USC Norris Comprehensive Cancer Center (Los Angeles, CA, USA), and as the President of the American Association for Cancer Research (AACR). Dr. Jones holds the title of Distinguished Professor and is currently the Director of the Center for Epigenetics at Van Andel Research Institute. He is also the co-founder of Stand Up To Cancer (SU2C) Epigenetics Dream Team, and is on the scientific advisory boards of Cancer Research UK Cambridge Institute at Cambridge University, and of Blueprint, a large-scale epigenome project gathering 42 leading European universities and research institutes. Dr. Jones is a member of the National Academy of Sciences, USA.
The Cancer Epigenetics Society is looking forward to Dr. Peter Jones leadership in establishing the highest possible standards of research quality and rigor in the field of DNA methylation research published in the Cancer Epigenetics Society journals (Cancer Epigenetics Society news; March 13, 2017).